שווי כולל של החברה: ABVC BioPharma, Inc (ABVC)

ABVC BioPharma focuses on the global expansion of its plant-based product line for treating ADHD and depression through clinical trials. Market price action reflects an Enterprise Value of 32.54. Market capitalization is supported by milestone payments from pharma partners for innovation success, while the company derives its primary revenue from licensing agreements for the development of drugs targeting psychiatric disorders and oncology.

ABVC BioPharma develops high-risk, early-stage biotechnological projects. The enterprise value sums the market capitalization and net debt, reflecting the total acquisition price of the business. Analyzing the enterprise value structure allows for the identification of hidden risk overvaluation during market volatility. For the issuer, this indicator is critical due to potential capital shortages for research. The trend of this metric demonstrates the current investor consensus regarding the viability of the developments.